We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -6.86% | 1.90 | 1.84 | 1.96 | 2.01 | 2.00 | 2.00 | 1,925,128 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.76 | 6.7M |
TIDMIMM
RNS Number : 4907X
Immupharma PLC
24 November 2017
24 NOVEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its Directors, non-executive Directors, employees and consultants representing 5.26% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options").
The exercise price for the Options is 98.62 pence being the closing middle market share price on 23 November 2017. The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.
Options granted to Executive Directors and employees
Upon the recommendation of the Company's remuneration committee, the Company has granted 4,875,000 of the Options to the Company's Executive Directors and certain other employees pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan"). The amount of Options granted on 24 November 2017 to the Executive Directors is summarised in the following table:
Director Ordinary Shares under Option ------------------- ---------------------- Dimitri Dimitriou 1,500,000 ------------------- ---------------------- Robert Zimmer 1,875,000* ------------------- ----------------------
*includes 375,000 Options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.
Messrs Dimitriou and Zimmer currently have the following interests in issued Ordinary Shares:
Director Number of Ordinary % of issued share Shares capital at 24 November 2017 ------------------- ------------------- ------------------ Dimitri Dimitriou 3,567,430 2.69 ------------------- ------------------- ------------------ Robert Zimmer 25,344,514* 19.12 ------------------- ------------------- ------------------
*includes 792,961 shares held by Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.
Following the grant of the options referred to above, Messrs Dimitriou and Zimmer will have the following interests in share options in the Company:
Director Number of Exercise Price Expiry Date options ------------------ ------------ --------------- ------------ Dimitri Dimitriou 140,000 86.50p 04.02.2019 1,000,000 50.25p 30.03.2027 1,500,000 98.62p 24.11.2027 ------------------ ------------ --------------- ------------ Robert Zimmer 200,000* 86.50p 04.02.2019 50,000* 90.75p 24.11.2021 100,000* 43.88p 02.06.2026 1,250,000* 50.25p 30.03.2027 1,875,000* 98.62p 24.11.2027 ------------------ ------------ --------------- ------------
*includes options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company
Following this grant of Options summarised above, the total number of share options outstanding pursuant to the 2017 Plan will be 8,125,000 representing 6.15% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. 2,005,000 Options remain outstanding pursuant to the Company's previous share option plan. Together, there are 10,130,000 Options outstanding representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.
Options granted to Non-executive Directors
The Company has also granted certain Options to Non-executive Directors as summarised in the following table:
Director Ordinary Shares under Option ----------------- ---------------------- Tim McCarthy 1,500,000 ----------------- ---------------------- Franco di Muzio 300,000 ----------------- ---------------------- Stephane Mery 300,000 ----------------- ----------------------
Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:
Director Number of Ordinary % of issued share Shares capital at 23 November 2017 ----------------- ------------------- ------------------ Tim McCarthy 38,462 0.03% ----------------- ------------------- ------------------ Franco di Muzio 99,412 0.08% ----------------- ------------------- ------------------ Stephane Mery 21,490 0.02% ----------------- ------------------- ------------------
Following the grant of the Options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:
Director Number of Exercise Price Expiry Date Ordinary Shares under Option -------------- ----------------- --------------- ------------ Tim McCarthy 500,000 43.88p 02.06.2026 1,000,000 56.75p 12.07.2027 1,500,000 98.62p 24.11.2027 -------------- ----------------- --------------- ------------ Franco di 100,000 86.50p 04.02.2019 Muzio 100,000 43.88p 02.06.2026 200,000 56.75p 12.07.2027 300,000 98.62p 24.11.2027 -------------- ----------------- --------------- ------------ Stephane Mery 100,000 43.88p 02.06.2026 200,000 56.75p 12.07.2027 300,000 98.62p 24.11.2027 -------------- ----------------- --------------- ------------
Total Share Options
As stated above, the total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The total options outstanding that have been granted to non-employees and consultants is 5,185,000. The total warrants outstanding is 153,850. Taken altogether, there are currently 15,468,850 outstanding options and warrants, representing 11.67% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.
This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
ImmuPharma plc (www.immupharma.co.uk) --------------------------------------- --------------------- Tim McCarthy, Chairman Lisa Baderoon, Head of Investor +44 (0) 20 7152 Relations 4080 Twitter: @immupharma +44 (0) 7721 413496 --------------------------------------- --------------------- Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, Corporate Finance David Hignell, Corporate Finance Jamie Spotswood, Corporate Finance +44 (0) 20 3861 Rob Rees, Corporate Broking 6625 --------------------------------------- ---------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEBIBTTMBATBIR
(END) Dow Jones Newswires
November 24, 2017 08:32 ET (13:32 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions